本文選題：盆腔子宮內(nèi)膜異位癥 + 保守術(shù)后��； 參考：《中華中醫(yī)藥雜志》2017年08期

【摘要】：目的:研究活血消異方抑制盆腔子宮內(nèi)膜異位癥保守術(shù)后復(fù)發(fā)的有效性和安全性。方法:選擇符合診斷標(biāo)準(zhǔn)并簽署知情同意書的子宮內(nèi)膜異位癥患者66例,給予活血消異方并于術(shù)后第1個(gè)月經(jīng)周期第1-5天進(jìn)行第1次訪視,治療期間每個(gè)月經(jīng)周期訪視1次至術(shù)后12月。術(shù)后3、6、9、12個(gè)月分別評(píng)價(jià)復(fù)發(fā)情況、妊娠情況、血清CA125水平及用藥安全性。結(jié)果:納入66例患者中,脫落6例,共60例納入統(tǒng)計(jì);術(shù)后6個(gè)月內(nèi)可能是保守術(shù)后復(fù)發(fā)的高發(fā)期,以25-29歲復(fù)發(fā)數(shù)最多;活血消異方治療盆腔子宮內(nèi)膜異位癥氣滯血瘀證保守術(shù)后12個(gè)月內(nèi)總復(fù)發(fā)率13.3%(8/60);單純卵巢型子宮內(nèi)膜異位癥患者最多,術(shù)后12個(gè)月內(nèi)總復(fù)發(fā)率12.0%(6/50),卵巢型子宮內(nèi)膜異位癥合并浸潤型的術(shù)后12個(gè)月內(nèi)總復(fù)發(fā)率11.1%(1/9),卵巢型子宮內(nèi)膜異位癥合并盆腔腹膜型的復(fù)發(fā)率最高,術(shù)后12個(gè)月內(nèi)總復(fù)發(fā)率100%(1/1);r-AFS分期中Ⅲ、Ⅳ期患者的復(fù)發(fā)率較高,術(shù)后12個(gè)月內(nèi)總復(fù)發(fā)率17.8%(8/45);60例病例中,有生育要求的患者26例,術(shù)后12個(gè)月內(nèi)總?cè)焉锫蕿?1.5%(16/26);本方對(duì)病患術(shù)后3個(gè)月血清CA125水平有一定下調(diào)作用;僅有1例患者出現(xiàn)服藥后不適,與患者藥物性肝炎病史有關(guān)。結(jié)論:活血消異方對(duì)抑制盆腔子宮內(nèi)膜異位癥氣滯血瘀證保守術(shù)后復(fù)發(fā)有效且安全,以單純卵巢型子宮內(nèi)膜異位癥效果最佳。
[Abstract]:Objective: to study the efficacy and safety of Huoxue Xiaoyi decoction (HXXXY) in inhibiting the recurrence of pelvic endometriosis after conservative operation. Methods: 66 patients with endometriosis who met the diagnostic criteria and signed an informed consent were given Huoxue Xiaodiao recipe and the first visit was conducted on the 1st and 5th day of the menstrual cycle after operation. Visits were made once per menstrual cycle to 12 months after treatment. Recurrence, pregnancy, serum CA125 levels and drug safety were evaluated at 3, 6 and 12 months postoperatively. Results: among the 66 patients, 6 cases were dropped out, 60 cases were included in the statistics, the recurrence period may be high in 6 months after operation, and the number of recurrence in 25-29 years old is the most. The total recurrence rate was 13.3% (8 / 60) in 12 months after treatment of pelvic endometriosis with Qi stagnation and blood stasis syndrome. The total recurrence rate was 12.0% (6 / 50) in 12 months after operation, 11.1% (1 / 9) in ovarian endometriosis with infiltration, and the highest in ovarian endometriosis with pelvic peritoneal type. Within 12 months after operation, the total recurrence rate was 100% (1 / 1). The recurrence rate of stage 鈪，

本文編號(hào)：2073307